These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29873030)

  • 21. Cerebrospinal fluid chitinase-3-like 2 and chitotriosidase are potential prognostic biomarkers in early multiple sclerosis.
    Møllgaard M; Degn M; Sellebjerg F; Frederiksen JL; Modvig S
    Eur J Neurol; 2016 May; 23(5):898-905. PubMed ID: 26872061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.
    Modvig S; Degn M; Roed H; Sørensen TL; Larsson HB; Langkilde AR; Frederiksen JL; Sellebjerg F
    Mult Scler; 2015 Dec; 21(14):1761-70. PubMed ID: 25698172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
    Collins MA; An J; Hood BL; Conrads TP; Bowser RP
    J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome.
    Rouwette M; Somers K; Govarts C; De Deyn PP; Hupperts R; Van Wijmeersch B; De Jong BA; Verbeek MM; Van Pesch V; Sindic C; Villar LM; Álvarez-Cermeño JC; Stinissen P; Somers V
    J Neurochem; 2012 Nov; 123(4):568-77. PubMed ID: 22958230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.
    Brettschneider J; Petzold A; Junker A; Tumani H
    Mult Scler; 2006 Apr; 12(2):143-8. PubMed ID: 16629417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis.
    Tortorella C; Direnzo V; Ruggieri M; Zoccolella S; Mastrapasqua M; D'Onghia M; Paolicelli D; Cuonzo FD; Gasperini C; Trojano M
    Mult Scler; 2018 Jul; 24(8):1039-1045. PubMed ID: 28537100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
    PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome.
    Orbach R; Gurevich M; Achiron A
    Mult Scler; 2014 Jan; 20(1):35-42. PubMed ID: 23722323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis.
    Kroksveen AC; Jaffe JD; Aasebø E; Barsnes H; Bjørlykke Y; Franciotta D; Keshishian H; Myhr KM; Opsahl JA; van Pesch V; Teunissen CE; Torkildsen Ø; Ulvik RJ; Vethe H; Carr SA; Berven FS
    Proteomics; 2015 Oct; 15(19):3361-9. PubMed ID: 26152395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome.
    Sladkova V; Mareš J; Lubenova B; Zapletalova J; Stejskal D; Hlustik P; Kanovsky P
    Neurol Res; 2011 May; 33(4):415-20. PubMed ID: 21535941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid lipocalin 2 in patients with clinically isolated syndromes and early multiple sclerosis.
    Khalil M; Renner A; Langkammer C; Enzinger C; Ropele S; Stojakovic T; Scharnagl H; Bachmaier G; Pichler A; Archelos JJ; Fuchs S; Seifert-Held T; Fazekas F
    Mult Scler; 2016 Oct; 22(12):1560-1568. PubMed ID: 26762671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subclinical central inflammation is risk for RIS and CIS conversion to MS.
    Rossi S; Motta C; Studer V; Macchiarulo G; Germani G; Finardi A; Furlan R; Martino G; Centonze D
    Mult Scler; 2015 Oct; 21(11):1443-52. PubMed ID: 25583841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of Chitinase 3-like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis.
    Floro S; Carandini T; Pietroboni AM; De Riz MA; Scarpini E; Galimberti D
    Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35534236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble CD27 Levels in Cerebrospinal Fluid as a Prognostic Biomarker in Clinically Isolated Syndrome.
    van der Vuurst de Vries RM; Mescheriakova JY; Runia TF; Jafari N; Siepman TA; Hintzen RQ
    JAMA Neurol; 2017 Mar; 74(3):286-292. PubMed ID: 28055081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
    Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
    J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers.
    Ottervald J; Franzén B; Nilsson K; Andersson LI; Khademi M; Eriksson B; Kjellström S; Marko-Varga G; Végvári A; Harris RA; Laurell T; Miliotis T; Matusevicius D; Salter H; Ferm M; Olsson T
    J Proteomics; 2010 Apr; 73(6):1117-32. PubMed ID: 20093204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased cerebrospinal fluid chitinase 3-like 1 and neurofilament light chain in pediatric acquired demyelinating syndromes.
    Boesen MS; Jensen PEH; Magyari M; Born AP; Uldall PV; Blinkenberg M; Sellebjerg F
    Mult Scler Relat Disord; 2018 Aug; 24():175-183. PubMed ID: 30055504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis.
    Mahler MR; Søndergaard HB; Buhelt S; von Essen MR; Romme Christensen J; Enevold C; Sellebjerg F
    Mult Scler Relat Disord; 2020 Oct; 45():102391. PubMed ID: 32679525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS.
    Novakova L; Singh AK; Axelsson M; Ståhlman M; Adiels M; Malmeström C; Zetterberg H; Borén J; Lycke J; Cardell SL; Blomqvist M
    J Neurochem; 2018 Aug; 146(3):322-332. PubMed ID: 29676479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
    Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.